Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events-Reference-Cited by-同舟云学术

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events

Published:2017-11-18 Issue:18 Volume:77 Page:2025-2036
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Al-Salama Zaina T.,Keating Gillian M.,Keam Susan J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-017-0844-8/fulltext.html

Reference43 articles.

1. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25(14):1197–207.

2. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12(1):30–47.

3. Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet. 2015;386(9990):292–302.

4. European Medicines Agency. Brilique (ticagrelor) 60 mg film-coated tablets: EU summary of product characteristics. 2015. http://www.ema.europa.eu/ . Accessed 7 Nov 2017.

5. Deeks ED. Ticagrelor: a review of its use in the management of acute coronary syndromes. Drugs. 2011;71(7):909–33.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of myricetin and quercetin on ticagrelor metabolism and the underlying mechanism;Chemico-Biological Interactions;2024-04

2. Long-term dual antiplatelet therapy and nuisance bleeding: impact on quality of life;Monaldi Archives for Chest Disease;2022-11-18

3. Carbohydrate-based drugs launched during 2000−2021;Acta Pharmaceutica Sinica B;2022-10

4. Disnea secundaria a ticagrelor posterior a arteriografía coronaria. Reporte de caso;Revista Médicas UIS;2022-03-18

5. Supramolecular synthon hierarchy in cyclopropyl-containing peptide-derived compounds;CrystEngComm;2022